Get started
Dr. Reddy's Laboratories LtdDr. Reddy's Laboratories LtdDr. Reddy's Laboratories Ltd

Dr. Reddy's Laboratories Ltd

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

RDY trade ideas

Indian Pharma Sector Stocks - It Is All About RotationSo what's ailing Indian Pharma sector stocks? Those who really looked like on steroids are suddenly behaving like they have swallowed over dose of laxatives. Few environmental changes are to blame, 1. ) Rotation Yes folks, those who rode it from Rs. 100 a stock to 1500 are taking profit and putting that money to some other sector where they believe market it going to perform well. Look at Reliance, a single stock has gobbled up many thousand crore in its rally. From where that money came to buy such stocks in other sector? Of course some from new gullible SIP investors ( more on that in upcoming post :) ) etc and some from rotation. 2. ) Change In Tone of Governments Still it's difficult to justify the quantitative effect on Pharma stocks but certainly this is also a factor which will keep on weighing the stocks in future. Many countries are being rhetoric about fixing the drug prices and that is headline risk as well as bottom line risk. 3. ) Too Much Good Has Been Priced In How much is too much?! ;) That question is never going to have perfect answer in stock market because it's all about psychology. But in general, when anybody look at the chart and say, wow what a rise of few hundred or thousand percent gain ! then it is time to be cautious. Because even though fundamentals are supportive for such rise, market needs confirmation and will wait to digest such meteoric rise. We had great trades in Pharma stocks like, Dr Reddy Cipla Glaxo Lupin Auropharma Divis Laboratories etc.. But now it is time to pause and let them collapse until they become attractive again !
NSE:DRREDDY
by BombayBulls
DRREDDY in BUY modeFundamentally a STRONG company and it had recent news for its upmove Dr Reddy's Laboratories has expanded strategic collaboration with Amgen, one of the world's leading independent biotechnology companies, to market and distribute three of Amgen's medicines in India in the therapy areas of oncology and osteoporosis. Under the terms of the collaboration, the company will commercialise XGEVA'(denosumab), Vectibix' (panitumumab) and Prolia (donosumab) in India. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4382.95 on 20-Oct-2015 and a 52 week low of Rs. 2750.00 on 21-Jan-2016. The promoters holding in the company stood at 26.37%, while institutions and non-institutions held 41.16% and 15.64% respectively. Dr. Reddy’s Laboratories has been listed as an Index component of the Dow Jones Sustainability Indices (DJSI) 2016 in the Pharmaceuticals, Biotechnology & Life Sciences Industry Group. The pharma major has been recognized for its corporate sustainability leadership and is the only pharmaceutical company on the Index of Emerging Markets. The listing was based on 22 criterion, with Dr. Reddy’s receiving high scores for Product Quality and Recall Management, Codes of Business Conduct, Environmental Reporting, Corporate Citizenship and Philanthropy.
NSE:DRREDDYLong
by agan